Nanotech Investing Universal Ibogaine Provides Bi-weekly Default Status Report on 2025 Year-end Filings and Update on Restructuring Process
Nanotech Investing Anixa Biosciences Announces Transfer of IND for Breast Cancer Vaccine from Cleveland Clinic
Nanotech Investing Anixa Biosciences Announces Positive Phase 1 Data for Investigational Breast Cancer Vaccine; Primary Endpoints Were Met and Immune Response Observed in 74% of Participants
Nanotech Investing Anixa Biosciences to Participate in Water Tower Research Fireside Chat on Monday, December 15, 2025
Nanotech Investing Satellos Receives Clearance by U.S. FDA and Global Regulators to Initiate Pediatric Phase 2 Study of SAT-3247 for Duchenne Muscular Dystrophy
Nanotech Investing Vaxcyte Doses First Participants in the OPUS Phase 3, Noninferiority Trial Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults
Nanotech Investing Innovent Announces Inclusion of Seven Innovative Drugs including TYVYT New Indication and SYCUME in China's National Reimbursement Drug List
Nanotech Investing Nuvation Bio Announces Publication of Positive Phase 2 Study Results for Safusidenib for the Treatment of Grade 2 IDH1-Mutant Glioma in Neuro-Oncology
Nanotech Investing Universal Ibogaine advises further on application for Management Cease Trade Order
Nanotech Investing Soleno Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference
Nanotech Investing Satellos Announces Publication in Nature Communications Supporting its Novel Treatment Approach for Duchenne Muscular Dystrophy
Nanotech Investing Anixa Biosciences Announces World Health Organization Approval of International Non-Proprietary Name for its CAR-T Therapy, Marking a Key Milestone Toward Global Recognition and Future Commercialization
Freegold Ventures Limited Announces Upsized Brokered Private Placement Financing from $30 Million to Up to $50 Million
